Références
De Bono JS, Logothetis CJ, Molina A, et al. (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364: 1995–2005
Loriot Y, Bianchini D, Ileana E, et al. (2013) Antitumor activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 24(7): 1807–1812
Noonan KL, North S, Bitting L, et al. (2013) Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 24(7): 1802–1807
Scher HI, Fizazi K, Saad F, et al. (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367: 1187–1197
Références
du Bois A, Lück HJ, Meier W, et al. (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95(17): 1320–1329
Katsumata N, Yasuda M, Takahashi F, et al. (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374(9698): 1331–1338
Norton L (2001) Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist 6(Suppl 3): 30–35
Ozols RF, Bundy BN, Greer BE, et al. (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21(17): 3194–3200
Pignata S, Scambia G, Lauria R, et al. (2013) A randomized multicenter phase III study comparing weekly versus every 3 weeks carboplatin (C) plus paclitaxel (P) in patients with advanced ovarian cancer (AOC): Multicenter Italian Trials in Ovarian Cancer (MITO-7)-European Network of Gynaecological Oncological Trial Groups (ENGOT-ov-10) and Gynecologic Cancer Intergroup (GCIG) trial. J Clin Oncol 31(Suppl; abstr LBA5501)
Références
Perez A, Neskey DM, Wen J, et al. (2012) Abstract 2521: targeting CD44 in head and neck squamous cell carcinoma (HNSCC) with a new humanized antibody RO5429083. Cancer Res 72: 22521. doi: 10.1158/1538-7445.AM2012-2521
Seluanov A, Hine C, Azpurua J, et al. (2009) Hypersensitivity to contact inhibition provides a clue to cancer resistance of naked mole-rat. Proc Natl Acad Sci U S A 106: 19352–19357. doi: 10.1073/pnas.0905252106
About this article
Cite this article
Brèves de l’AERIO. Oncologie 15, 543–547 (2013). https://doi.org/10.1007/s10269-013-2335-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10269-013-2335-1